Project leaders: Olivier PROVOT , Jérôme BIGNON , Sébastien APCHER , Charles TRUILLET , Simon SPECKLIN
For diagnosis and therapy - (15/03/2024)
Azaisocoquine is a derivative of a natural molecule with proven anti-tumour activity, but with major drawbacks such as cardiotoxicity and high instability. This derivative has been synthesised by the CoSMIT team (BioCIS) and no longer appears to have the drawbacks of the original molecule. The project brings together immunologists from Gustave Roussy with chemists and biologists from Paris-Saclay, with the aim of studying the fate of azaisocoquine in the body, in particular its biodistribution in the organs, analysed by PET imaging in order to define the type of cancer to be targeted and its elimination from the body. Based on the distribution and elimination results, the cytotoxic activity of azaisocoquine will be studied against a panel of human and murine cancer lines. In vivo tests will then be carried out on tumour-bearing mice to measure the impact of the treatment on tumour growth.
Contact : Olivier PROVOT (BioCIS, Faculté de pharmacie, Université Paris-Saclay)
